MAHWAH, N.J., March 10, 2025 /PRNewswire/ -- Glenmark Therapeutics Inc., USA (Glenmark) is pleased to announce the launch1 of Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC ...

Glenmark Pharmaceuticals has introduced a new constipation treatment, polyethylene glycol 3350 powder, to the US market. This launch aims to fulfill the rising demand for a fresh supplier in the ...

Glenmark Therapeutics Inc., USA announced today the launch of its Polyethylene Glycol 3350, Powder for Solution, an over-the-counter laxative that will compete directly with Bayer’s MiraLAX.

Mahwah: Glenmark Pharmaceuticals Inc., USA has announced the launch of Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) ...

GLENMARK) is a research–led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology.

GLENMARK) is a research–led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology.

today announced that Glenmark had received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to market Winlevi® in the United Kingdom. Winlevi® is a topical treatment ...

Glenmark Pharmaceuticals Ltd. (BSE: 532296) (NSE: GLENMARK) is a research–led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on ...